176 related articles for article (PubMed ID: 24421178)
21. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
22. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
Le Rhun E; Bertrand N; Dumont A; Tresch E; Le Deley MC; Mailliez A; Preusser M; Weller M; Revillion F; Bonneterre J
Eur J Cancer; 2017 Dec; 87():189-198. PubMed ID: 29103666
[TBL] [Abstract][Full Text] [Related]
23. PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.
Eze N; Lee JW; Yang DH; Zhu F; Neumeister V; Sandoval-Schaefer T; Mehra R; Ridge JA; Forastiere A; Chung CH; Burtness B
Oral Oncol; 2019 Apr; 91():69-78. PubMed ID: 30926065
[TBL] [Abstract][Full Text] [Related]
24. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
[TBL] [Abstract][Full Text] [Related]
25. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
26. Genomic Database Analysis for Head and Neck Cancer Prevention Targets: MTOR Signal Transduction Pathway.
Koenigsberg C; Ondrey FG
Anticancer Res; 2020 Oct; 40(10):5417-5421. PubMed ID: 32988862
[TBL] [Abstract][Full Text] [Related]
27. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
28. Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review.
de Kort WWB; Spelier S; Devriese LA; van Es RJJ; Willems SM
Mol Diagn Ther; 2021 Mar; 25(2):123-136. PubMed ID: 33686517
[TBL] [Abstract][Full Text] [Related]
29. MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
Liu F; Zhao X; Qian Y; Zhang J; Zhang Y; Yin R
Biomed Pharmacother; 2017 Dec; 96():229-237. PubMed ID: 28987947
[TBL] [Abstract][Full Text] [Related]
30. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Cohen Y; Goldenberg-Cohen N; Shalmon B; Shani T; Oren S; Amariglio N; Dratviman-Storobinsky O; Shnaiderman-Shapiro A; Yahalom R; Kaplan I; Hirshberg A
Oral Oncol; 2011 Oct; 47(10):946-50. PubMed ID: 21824802
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
34. Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Al-Amri AM; Vatte C; Cyrus C; Chathoth S; Hashim TM; Mohamed YS; Al Ali R; Alsaid A; Al Ali A
Cancer Biomark; 2016; 16(3):377-83. PubMed ID: 26889984
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA 744-3p promotes MMP-9-mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma.
Li JZ; Gao W; Lei WB; Zhao J; Chan JY; Wei WI; Ho WK; Wong TS
Oncotarget; 2016 Sep; 7(36):58218-58233. PubMed ID: 27533461
[TBL] [Abstract][Full Text] [Related]
36. The associations of hub gene polymorphisms in PI3K/AKT/mTOR pathway and Schistosomiasis Japonica infection and hepatic fibrosis.
Xiao Q; Yu H; Zhu X
Infect Genet Evol; 2020 Nov; 85():104423. PubMed ID: 32554084
[TBL] [Abstract][Full Text] [Related]
37. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
38. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
40. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
